There is evidence of a correlation between mitotane plasma levels and antineoplastic efficacy. Studies have demonstrated an objective response rate of 55%-66% in patients whose plasma levels were above 14 mg/L, whereas lower levels were associated with lack of efficacy (4) (5) (6) . The concept that mitotane levels predict treatment response has been confirmed in a large multicenter study (7) . Accordingly, monitoring plasma levels is considered to be as standard of care.
Information on mitotane pharmacokinetics primarily originates from a study performed in 1960 (8) . It appears that 35%-40% of the drug is absorbed from the gastrointestinal tract and is stored primarily in adipose tissues.
This may explain the time lag of 4 weeks to several months necessary for reaching target plasma levels (9 -12) . Thus, higher starting doses have been proposed to earlier reach the therapeutic window (13) . In addition, some groups suggested that mitotane plasma level after 2-4 weeks might predict whether the patient reaches the target level within a short time, justifying monotherapy in these patients (2, 13) .
Metabolism of mitotane results in the formation of two metabolites, 2,4-dichlorodiphenyl acetic acid (DDA) and 1,1-(o,p_-dichlorodiphenyl)-2,2-dichloroethene (DDE), of whichDDAhas been identified as the major circulating and excreted metabolite (14) . A recent retrospective study in a group of 91 patients with ACC demonstrated that DDA plasma levels greater than 92 mg/L may be associated with tumor response (7) .
Tolerability is a matter of concern because adverse effects occur frequently and are also related in part to drug levels. However, the number of patients who discontinue therapy can be minimized by regular counseling about the management of adverse effects, careful adjustment of hormone replacement therapies, and tailoring of mitotane dosage based on plasma levels and side effects (15) . Time to reach a mitotane plasma level of 14 mg/L was determined as a post hoc end point. In addition, we examined whether mitotane levels assessed early in therapy were predictive for reaching 14 mg/L within 12 weeks. This is the first prospective multicenter study aimed at improving knowledge on the pharmacokinetic properties of mitotane.
Materials and Methods

Patients
The main eligibility criteria were histologically confirmed locally advanced or metastatic adrenocortical carcinoma not amenable to radical surgical resection, radiologically monitorable disease, Eastern Cooperative Oncology Group (ECOG) performance status 0-2, life expectancy longer than 3 months, age 18 years or older, adequate hematological and biochemical function, effective contraception, written informed consent, and the ability to comply with study procedures. Exclusion criteria were previous treatment with mitotane, cytotoxic chemotherapy or experimental drugs for ACC, history of prior malignancy, renal or hepatic insufficiency, pregnancy, breast-feeding, presence of active infection, decompensated heart failure, myocardial infarction, or revascularization procedure in the last 6 months. The protocol was approved by the institutional ethics committees and all patients gave informed consent.
Study design and treatment
The study was an international prospective, open-label, multicenter study. Treatment with mitotane was initiated at least 2 weeks prior to the start of cytotoxic chemotherapy. Assignment to one of two dosing regimens was at the discretion of the local investigator without detailed inclusion criteria. A detailed summary of both regimens is provided in Table 1 . Mitotane was taken orally in three daily doses with food. The predefined study duration for each patient was 12 weeks.
Measurement of mitotane and metabolites
Mitotane plasma level was assessed weekly during the first 8 weeks and then at weeks 10 and 12. Sampling was performed in the morning at least 12 hours after the last dose. Quantitative analyses of mitotane,DDA,andDDEwere performed by Parexel (Bloemfontein, South Africa) using HPLC (17) . 
Statistical analysis
Only limited data were available on inter-and intrasubject variability of mitotane pharmacokinetics, precluding a classical sample size calculation. It was estimated that it would be necessary to recruit eight patients per subgroup (high/low dose, EDP/streptozotocin chemotherapy) to investigate differences between both dosing regimens and to evaluate safety. Assuming some dropouts, the study aimed at an inclusion of 40 patients. Table 2 displays demographic data according to the subgroups. Because all participants had to sign informed consent for the FIRM-ACT study at inclusion, the intention was to administer chemotherapy to all participants. However, 17 patients were not randomized in FIRM-ACT and did not receive chemotherapy during this substudy due to indolent disease (n _ 8), rapid progression of disease (n _ 3), patient's refusal (n _ 2), early death (n _ 2), revision of tumor staging (n _ 1), or violation of inclusion criteria (n _ 1).
As stated in the study protocol, all 40 patients were included in safety analyses. Eight patients were excluded from the per-protocol analysis of pharmacokinetics: three patients died after 19, 21, and 24 days due to disease progression (n _ 2) and pulmonary embolism (PE) (n _ 1), respectively; in two patients protocol deviations resulted in missing at least three consecutive pharmacokinetic measurements, two patients did not respect the inclusion criteria and were rapidly excluded (after 4 and 6 d of treatment, respectively), and one patient refused to continue mitotane after 14 days (Figure 1 ).
From the remaining 32 patients, four patients were excluded from analyses concerning cumulative doses because they discontinued the study before the projected end point at week 12: one patient died after 39 days, one patient It should be noted that mitotane plasma levels in most patients were still rising and no plateau was reached within 12 weeks (Figure 2A There were eighteen AEs (9%) related to general disorders.
General discomfort NCI-CTC grade 1 (n _ 6), asthenia (n _ 4), and fatigue (n _ 4) were most common events in this category. Most events were reported among patients on the high-dose regimen (n _ 16).
Fourteen AEs were related to metabolism and nutrition (7%); 10 occurred in the high-dose group. There were two grade 4 AEs: these were episodes of hypomagnesaemia and hypokalemia, both probably related to concomitant cytotoxic treatment with EDP. There were four events in the low-dose group, all hypercholesterolemia grade 2 or less.
Eighteen events were related to disorders of the nervous system (9%). Vertigo (n _ 6) and dizziness (n _ 5) were mostcommon.Regarding psychiatric AEs, there were four reports of anxiety attacks and two reports of insomnia.
Depression and hallucination were both reported once.
Changes in hepatic enzymes were seen frequently. After Four patients died during the study. Two patients died due to disease progression, one patient died after PE, and one patient died after severe cardiac failure, but these events were not considered drug related.
Hormonal parameters
Mean TSH did not change significantly over the course of this 12-week study, both in patients with high and low mitotane plasma levels (Table 4 In a previous study with 13 patients taking mitotane as first-line therapy, a correlation was observed between plasma levels and cumulative dose of mitotane (4). This suggests dose proportionality, which means that drug elimination is independent of the concentration present in the body (zero order reaction) rather than dependent (first order reaction).
Therefore,wespeculate that in clinical practice elimination of mitotane proceeds at a constant rate independent of the plasma concentration. This is supported by the stable levels ofDDAthat were observed after 4 weeks of treatment in both groups. Consequently, administration of higher doses should result in higher plasma levels in a shorter period of time. Because steady-state levels of mitotane had not been reached at week 12, it is tempting to speculate that a longer study duration would have demonstrated that high-dose mitotane reaches steady-state conditions earlier.
Our data confirm previous observations that the increase in plasma concentrations is in general slow and highly variable.
Obviously this behavior cannot be sufficiently explained by differences in dosing only, indicating that other factors contribute to this observation. Potential explanations are related to effects on enzyme induction by concomitant drugs and differences in intestinal absorption, which may also be affected by ingested food. Also, recent data show that individual genetic differences are significantly associated with mitotane levels (19) like this is known for other drugs (20, 21) . In the absence of baseline predictors, early measurements constitute the only signal whether a given patient hasahigh probability of reaching the therapeutic level in time (13) .
The observation that the high-dose schedule results in higher exposure in patients not receiving concomitant chemotherapy may be explained by multiple factors. It is possible that patients do not tolerate high mitotane doses in addition to chemotherapy or that physicians anticipate on the addition of chemotherapy by lowering the mitotane dosage.
However, cumulative doses were not different among these subgroups. Of note, treatment compliance could be a limitation in this respect. Also, the administration of cytotoxic chemotherapy could result in lower plasma levels due to drug interactions or impaired intestinal uptake (22) .
No significant difference was detected between the two groups regarding the frequency and severity of adverse events. This suggests that actual dosage is not the key determinant of adverse effects. Of note, we did not observe any (significant) correlation between adverse events and mitotane plasma level. However, it has to be acknowledged that 18 patients (45%) never reached a plasma level above 14 mg/L, and only six patients had measurements above 20 mg/L. Nevertheless, in our personal experience,AEscan usually be managed by adequate support, even when given in parallel to cytotoxic chemotherapy. An increase of GGT is well known and appeared in 100% of our patients. Observations in patients treated adjuvantly demonstrated that this is reversible (15, 23) .
Mitotane can induce hormonal effects soon after the onset of treatment. After 12 weeks a significant decrease in FT4 was detectable with a trend for a negative correlation between mitotane and FT4 levels. TSH and FT3 remained unchanged or were increased. It is known from previous research that mitotane use can lead to biochemical findings mimicking central hypothyroidism, ie, low FT4 with approximately normal FT3 and TSH levels (15) . Previously proposed explanations are a direct effect on the pituitary level, the induction of thyroid hormone metabolism, an increase in TBG levels, or changes in the thyroid hormone receptor's affinity for FT4 (22, 24, 25) . Also, interference with FT3, FT4, and/or TSH assays cannot be excluded.
Data on the influence of mitotane on sex hormones are scarce. In vitro studies showed that mitotane increases the synthesis of steroid binding protein (26, 27) . In our study, SHBG was markedly increased, whereas in males free T was decreased and LH was increased. Mitotane has been shown to bind the human estrogen receptor-_ with weak affinity, approximately 1000-fold weaker than that of estradiol itself (28) . Although the concentration of mitotane in plasma is about 5.0_105 times higher than estradiol levels in men, the presence of increased levels of LH makes a strong estrogenic effect of mitotane at the pituitary level not likely. A recent study demonstrated significantly decreased levels of dihydrotestosterone in mitotane-treated patients, which might be the reason for the increase of gonadotrophins (29) . Another possibility is mitotane-induced inhibition of T secretion, set off at least partially by an increase inSHBGand by decreased production (30) .
We acknowledge the limitations of our study. First, patients
were not randomized to a dosing regimen, which could have introduced bias. However, due to theembedmentof the study within the FIRM-ACT protocol, a second randomization was judged to be not feasible. Second, protocol deviations produced missing data, which made the study underpowered in several analyses. Furthermore, we acknowledge that more patients in the high-dose group had to be excluded from the pharmacokinetic analyses. However, as mentioned in Results, the reasons for exclusion are unlikely treatment related, and therefore, we do not expect that this fact influenced the conclusions.Afourth limitation is that steady-state levels of mitotane were not reached in all patients. However, due to the aggressiveness of the disease, a longer, comprehensive pharmacokinetic study would be very challenging for patients and investigators. Finally, the study was underpowered to assess differences in subgroups.
In conclusion, the high-dose starting regimen led to higher mitotane plasma levels within 12 weeks of treatment, and more patients reached the target level of 14 mg/L. Observed differences were greater in the subgroup of patients who did not receive concomitant cytotoxic chemotherapy, but the results were not statistically significant due to lack of power. The rate of AEs was similar between both groups, leading us to conclude that the high-dose approach is the preferred strategy in patients with mitotane monotherapy. However, in patients with reduced tolerability (eg, due to concomitant cytotoxic chemotherapy), a less aggressive regimen might be reasonable.
